PEPG earnings

– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of 7.3% observed with PGN-EDODM1 (n=6) versus 6.8% with placebo (n=2); Excluding one outlier patient, treatment group demonstrated mean splicing correction of 22.9% (n=5) – – Promising trends observed in vHOT in the PGN-EDODM1 treated group – – Company on track to report clinical data from 10 mg/kg multiple dose cohort in 2H 2026 with sufficient cash expected to fund operations into 2H 2027– – Conference call scheduled today at 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next genera

– Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today at 8:00 a.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). "These results far exceeded our expectations for splicing correctio

– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation

BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived

- PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 skipping approaches - - PGN-EDO51 was generally well-tolerated - - PepGen plans to initiate a Phase 2a multiple ascending dose (MAD) clinical trial in Duchenne muscular dystrophy (DMD) patients in 1H 2023 - - Data supports the potential of PepGen's Enhanced Delivery Oligonucleotide (EDO) platform in neuromuscular diseases - - Company to host conference call today at 8:00 a.m. ET to discuss these results - BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-sta